Ado-trastuzumab emtansine associated spider telangiectasia

Basit Öğe Kaydı
dc.authoridGursoy, Pinar/0000-0003-1392-6753
dc.authorscopusid56912355400
dc.authorscopusid56417418700
dc.authorscopusid57421517900
dc.authorwosidAcar, Ayda/ABB-4159-2020
dc.contributor.authorGursoy, Pinar
dc.contributor.authorAcar, Ayda
dc.contributor.authorAcikalin, Taner
dc.date.accessioned2023-01-12T20:03:56Z
dc.date.available2023-01-12T20:03:56Z
dc.date.issued2022
dc.departmentN/A/Departmenten_US
dc.description.abstractIntroduction Breast cancer is the most common cancer in women. Human epidermal growth factor receptor 2 (HER2) positivity rate is 20% and generally has a poor prognosis. Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate consisting of HER2 target monoclonal antibody trastuzumab and microtubule inhibitor emtansine. The most common side effects are fatigue, diarrhea, anemia, and it is generally a safe and tolerable agent. Case report In our case, we reported our patient who developed mucosal and cutaneous telangiectasia after T-DM1 treatment and who had a complete response in metastases after skin lesions. Management and Outcome While no side effects were observed during the use of T-DM1 for HER2 positive disease, nose bleeding and spider telangiectasia on the skin developed in the 9th month of the treatment. In these lesions, which did not require any treatment, no regression was observed during T-DM1 treatment. Discussion We think that T-DM1, which was detected with a low incidence of skin toxicity in studies, may form telangiectatic lesions due to vascular dilatation through emtansine, and therefore care should be taken in the treatment of T-DM1.en_US
dc.identifier.doi10.1177/10781552211073878
dc.identifier.endpage988en_US
dc.identifier.issn1078-1552
dc.identifier.issn1477-092X
dc.identifier.issue4en_US
dc.identifier.pmid35040682en_US
dc.identifier.scopus2-s2.0-85123236207en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage986en_US
dc.identifier.urihttps://doi.org/10.1177/10781552211073878
dc.identifier.urihttps://hdl.handle.net/11454/77743
dc.identifier.volume28en_US
dc.identifier.wosWOS:000748736600001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofJournal of Oncology Pharmacy Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBreast canceren_US
dc.subjecthuman epidermal growth factor receptor 2 (HER2)en_US
dc.subjectAdo-trastuzumab emtansine (T-DM1)en_US
dc.subjectBreast-Canceren_US
dc.subjectLapatiniben_US
dc.subjectSurvivalen_US
dc.titleAdo-trastuzumab emtansine associated spider telangiectasiaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu